US stocks rally after better inflation data

Sign up now: Get ST's newsletters delivered to your inbox

Traders work on the floor of the New York Stock Exchange during afternoon trading on July 26, in New York City.

Traders work on the floor of the New York Stock Exchange during afternoon trading on July 26, in New York City.

PHOTO: AFP

Follow topic:

NEW YORK - Wall Street stocks cheered a benign US inflation report on July 26, powering the market to a positive conclusion to the week despite weakness in tech shares in recent days.

The report showed that the personal consumption expenditures price index eased to an annual rate of 2.5 per cent in June, from 2.6 per cent, amounting to progress in a key US Federal Reserve indicator.

Futures markets overwhelmingly expect the Fed to cut interest rates in September.

The Dow Jones Industrial Average jumped 1.6 per cent to 40,589.34.

The broad-based S&P 500 advanced 1.1 per cent to 5,459.10, while the tech-rich Nasdaq Composite Index climbed 1.0 per cent to 17,357.88.

Stocks tumbled on July 24, led by a rout in tech shares, which have been seen as overvalued after strong gains in the first half of 2024. Despite the Nasdaq’s bounce on July 26, the index finished the week down more than 2 per cent.

“We continue to have slowing inflation and solid growth,” conditions “consistent with a soft landing thesis,” said Mr Angelo Kourkafas, of Edward Jones.

Mr Kourkafas expects more of a “rotation” away from technology to other sectors in the upcoming period.

Among individual companies, 3M shot up around 23 per cent after reporting better-than-expected earnings and lifting its full-year profit forecast. Analysts see the industrial heavyweight as well positioned following progress on major litigation issues that have dogged the company.

But Biogen dove 7.2 per cent after announcing European officials gave a negative reading on a new Alzheimer’s disease treatment. Biogen and partner Eisai said they would seek a reexamination of the decision.

DexCom, which supplies glucose monitoring systems for diabetes, plunged more than 40 per cent after lowering its sales forecast. AFP

See more on